**Tumor cell-targeted STING-agonist antibody-drug conjugates achieve potent anti-tumor activity by delivering tumor-specifically to mouse and human tumor models**

Naniya Matt Cebeliar, Travis Monnell, Kalli C. Caltcott, Jahna Soomer-James, Pamela Shaw, Rebecca Mosher, Keith Bentley, Susan Clardy, Marina Protopopova, Cheri Stevenson, Joshua D. Thomas, Alex Uttard, Dorin Toader, Jeremy Duvall, Raghdha A. Bukhalid, Marc Damelin, Timothy B. Lowinger

Mersana Therapeutics, Inc., Cambridge, MA

**Abstract**

**Tumor cell-targeted STING-agonist ADCs induce STING pathway in myeloid cells in an Fc- and antigen-dependent manner**

**RESULTS**

**Myeloid cells within dissociated tumor cells express Fcγ-RI and can induce histological damage in vivo with tumor cell-targeted STING-agonist ADC treatment**

**CONCLUSIONS**

All activity of tumor cell-targeted STING-agonist ADCs arises from delivery of ADCs to both myeloid cells and tumor cells.

- In this study, we demonstrate:
  - Fcγ-RI is the major receptor that mediates internalization of antigen-bound tumor cell-targeted STING-agonist ADCs into myeloid cells.
  - Delivery of STING-agonist specificity into Fcγ-Ri-expressing subpopulation of myeloid cells via a tumor cell-targeted ADC elicits potent anti-tumor activity.

**References:**